secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001140361-24-010088
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q4 rev $73.9M (+48%); FY rev $258.2M; raises FY24/25 guidance
----------------------------------------------------------------------------

- Q4 2023 total revenue $73.9M, up 48% YoY; FY 2023 total revenue $258.2M, up 68% YoY.
- Q4 adjusted net income $8.5M (vs loss $12.2M); FY adjusted net income $0.7M (vs loss $59.2M).
- FY 2024 guidance raised: revenue >$330M, net income >$65M, adjusted EBITDA >$90M.
- FY 2025 guidance raised: revenue >$380M, net income >$115M, adjusted EBITDA >$140M.
- Pipeline: S. pneumonia hyperimmune globulin potential peak rev $300-500M; ASCENIV pediatric study ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/0001140361-24-010088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036124010088/ef20022668_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-010088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer